| Document and Entity Information | Jan. 12, 2023 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Amendment Description | This Amendment No. 1 on Form 8-K/A (“Amendment No. 1”) amends the Current Report on Form 8-K of Cyteir Therapeutics, Inc. (the “Company”) filed with the Securities and Exchange Commission on January 19, 2023. The purpose of this Amendment No. 1 is to add Item 2.02, which had been inadvertently omitted from the original filing. |
| Entity Central Index Key | 0001662244 |
| Document Type | 8-K/A |
| Document Period End Date | Jan. 12, 2023 |
| Entity Registrant Name | Cyteir Therapeutics, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-40499 |
| Entity Tax Identification Number | 45-5429901 |
| Entity Address, Address Line One | 128 Spring St, Building A |
| Entity Address, Address Line Two | Suite 510 |
| Entity Address, City or Town | Lexington |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02421 |
| City Area Code | 857 |
| Local Phone Number | 285-4140 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value per share |
| Trading Symbol | CYT |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
